๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I, II trials of Lentinan in cancer patient

โœ Scribed by T. Taguchi

Publisher
Elsevier Science
Year
1980
Tongue
English
Weight
79 KB
Volume
2
Category
Article
ISSN
0192-0561

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The conduct of phase I-II clinical trial
The conduct of phase I-II clinical trials in children with cancer
โœ Pratt, Charles B. ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 677 KB

Phase I Clinical Trials in children with cancer are carried out with therapeutic intent, so as to define antileukemic/antitumor activity, dose-limiting toxicity, maximum tolerated dosage, and pharmacokinetics. These studies define a dosage of an agent or combination that may be used in a larger stud

Phase I trial of extracellular adenosine
Phase I trial of extracellular adenosine 5โ€ฒ-triphosphate in patients with advanced cancer
โœ Haskell, Charles M.; Wong, Maylene; Williams, Adrian; Lee, Le-Young ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 883 KB

Adenosine 5'-triphosphate (ATP) has antineoplastic activity in vitro and in murine tumor systems, but there are no data in humans defining its potential use as an antineoplastic agent. We conducted a Phase I study to determine the spectrum of toxicity, maximum safely tolerated dose (MTD), and pharma

Bayesian interim analysis of phase II ca
Bayesian interim analysis of phase II cancer clinical trials
โœ Daniel F. Heitjan ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 111 KB ๐Ÿ‘ 2 views

Many popular sequential phase II clinical trial designs optimize some criterion subject to constraints on the error probabilities at null and alternative values of the response rate. Such designs may forfeit optimality if one fails to conduct analyses strictly according to plan. Moreover, a decision

Preclinical safety testing of DISC-hGMCS
Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients
โœ Peter T. Loudon; Diane M. Blakeley; Mike E. G. Boursnell; Debbie A. Day; Imogen ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 235 KB

## Background: Disc-hgmcsf is a gh-deleted hsv-2 based vector expressing human gm-csf that is being developed for cancer immunotherapy. to support first clinical use, a range of preclinical safety studies were performed using disc-hgmcsf in addition to disc-murine-gmcsf and the backbone vector, ta-